from what was said earlier, it may not include any 'data on overall survival, progression free survival etc .. which may be because some patients are still under observation and they are waiting for all the data to accrue to the 6 month time-point before releasing a complete first cohort set of 'efficacy' data. We'll see I guess, but at some point we should be given a look at these outcomes.
If that is the case though for this SNO presentation, then we'll probably just get 'signs' of how CLTX is actually working in the patients... which at this early stage, is probably the more important thing to look out for. Which is why I've always said I'm more interested on the second abstract on how CLTX binds to GBM cells ... but on the first cohort bioactivity data, what we want to see is how how effective CLTX CAR-T is at kick starting the patients immune system/ bioactivity i.e. rate and level of proliferation of the immune response... and then importantly, how long does the (hopefully) elevated level of T cells / macrophages / NK cells persist within the patient.
If we see this spike in immune response, without getting 'efficacy' data ... I would be very confident in saying that it is 'working' .. because the whole point of CAR T therapy is to reprogram your immune system to recognise the cancer and then once they can do that, they recruit more T cells / macrophages / NK cells to start attacking the cancer with them .. and the higher that spike and the more persistent.. the greater the response.
Like a smoking gun, you don't get the spike in immune response without them finding targets to kill (shot) and then recruit (smoke).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)